Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

M. Duruisseaux, Anna Martínez‐Cardús, María Eréndira Calleja-Cervantes, +44

The Lancet Respiratory Medicine

Anti-pd-1 TreatmentMedicineRetrospective AnalysisCancer GenomicsBronchial Neoplasm +8

Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab

Adrien Costantini, Catherine Julié, Coraline Duménil, +8

OncoImmunology

ImmunologyImmunoeditingPathologyImmunotherapeuticsLow Sgranb +17

Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab

Julia Ouaknine Krief, Pierre Helly de Tauriers, Coraline Duménil, +9

Journal for ImmunoTherapy of Cancer

Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer

Etienne Giroux‐Leprieur, Guillaume Herbretau, Coraline Duménil, +8

OncoImmunology

Tumor ResponseProlonged Clinical BenefitAdvanced NsclcCancer DetectionMedicine +12

Clinical factors associated with early progression and grade 3–4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab

Coraline Duménil, Marie-Ange Massiani, Jennifer Dumoulin, +4

PLoS ONE

Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression

Etienne Giroux‐Leprieur, Zofia Hélias‐Rodzewicz, Paul Takam Kamga, +10

Journal for ImmunoTherapy of Cancer

Baseline Hedgehog Pathway Activation and Increase of Plasma Wnt1 Protein Are Associated with Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer

Camille Mehlman, Paul Takam Kamga, Adrien Costantini, +8

Cancers

Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%

Elvire Pons‐Tostivint, P. Hulo, V. Guardiolle, +14

Cancer Immunology Immunotherapy

Plasma Biomarkers Screening by Multiplex ELISA Assay in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

Adrien Costantini, Paul Takam Kamga, Catherine Julié, +9

Cancers

Is there a specific phenotype associated with the different subtypes of KRAS mutations in patients with advanced non-small-cell lung cancers?

Coraline Duménil, Thibault Vieira, Étienne Rouleau, +7

Lung Cancer

Somatic VariantTumor HeterogeneityMedicineGeneticsPathology +9